Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

4 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Nov. 10, 2022 ZYME S 10b5-1 2,475 $8.10 $20,048 14,449 Direct -14.62% Disposed 223.6% (price as of 2026-10-05)
Nov. 10, 2022 ZYME S 10b5-1 2,475 $8.10 $20,048 14,449 Direct -14.62% Disposed 223.6% (price as of 2026-10-05)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Nov. 10, 2022 ZYME Restricted Stock Unit Common Shares (5,885) · · 5,885 Disposed
Nov. 10, 2022 ZYME Restricted Stock Unit Common Shares (5,885) · · 5,885 Disposed

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

ZYME

Chief Medical Officer (10)
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2021 $456,653 · · · · · $17,438 $3,547,690

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.